TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1611329

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 128
Study: 30558079

Group type: EXPERIMENTAL
Intervention: Bosinji granule (2.5 g, 1.523 g of Bosinji extract)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Loxonin tablet (60 mg of loxoprofen)
Number of subjects: 74
Study: 27138023

Group type: EXPERIMENTAL
Intervention: Mepolizumab (10, 75, 250, or 750mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mepolizumab (75-750mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 35
Study: 25154469

Group type: EXPERIMENTAL
Intervention: Asynchronous e-learning modules
Number of subjects: 256

Group type: COMPARATOR
Intervention: Current education standards (Control)
Number of subjects: 256
Study: 22856518

Group type: EXPERIMENTAL
Intervention: GG genotype for rs2383206
Number of subjects: 611

Group type: COMPARATOR
Intervention: AA and AG genotypes for rs2383206
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: rs2383206 genotype
Number of subjects: 611
Study: 20566013

Group type: EXPERIMENTAL
Intervention: Electronic version of Urogenital Distress Inventory‐6 (UDI‐6) questionnaire
Number of subjects: 26

Group type: COMPARATOR
Intervention: Paper version of Urogenital Distress Inventory‐6 (UDI‐6) questionnaire
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electronic version of Incontinence Impact Questionnaire‐7 (IIQ‐7) questionnaire
Number of subjects: 26

Group type: COMPARATOR
Intervention: Paper version of Incontinence Impact Questionnaire‐7 (IIQ‐7) questionnaire
Number of subjects: 26
Study: 18094309

Group type: EXPERIMENTAL
Intervention: 0.03 mmol/kg gadofosveset
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadofosveset
Number of subjects: 185

Group type: COMPARATOR
Intervention: No contrast agent
Number of subjects: 185
Study: 17274520

Group type: EXPERIMENTAL
Intervention: High dose sublingual specific immunotherapy with a 6-grass-pollen mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12730632

Group type: EXPERIMENTAL
Intervention: Prostar XL device
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hydrochloride lidocaine containing 1% epinephrine as local anesthesia
Number of subjects: 109
Study: 10909169

Group type: EXPERIMENTAL
Intervention: Palivizumab 15 mg/kg
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study: 10323119

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study: 1728190

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (15 sessions)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined treatment (medication withdrawn at 16 or 24 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined treatment (24-week duration)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Desipramine (16 weeks)
Number of subjects: 71
Study: 6332274

Group type: EXPERIMENTAL
Intervention: Bypassed arteries with minimal atherosclerosis
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-bypassed arteries with minimal atherosclerosis
Number of subjects: 85
Study: 30978683

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 233
Study: 29505147

Group type: EXPERIMENTAL
Intervention: Parenteral Protein Calculator (PPC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 42
Study: 26542272

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Armodafinil
Number of subjects: 96
Study: 24281905

Group type: EXPERIMENTAL
Intervention: n‐3 FA‐enriched oral nutritional supplement (Supportan, 200 ml twice daily) providing 2.0 g EPA and 1.0 g DHA per day
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: n‐3 FA‐enriched oral nutritional supplement
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard isocaloric and isonitrogenous ONS
Number of subjects: 148
Study: 22128200

Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dienogest 1 mg daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dienogest 3 mg daily
Number of subjects: 102
Study: 19503774

Group type: EXPERIMENTAL
Intervention: Active-assisted stretching program (AA), performed twice weekly for eight weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (limited physical activity classes)
Number of subjects: 17
Study: 18385202

Group type: EXPERIMENTAL
Intervention: Classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (3 to 9 courses)
Number of subjects: 1475
Study: 16105989

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 1012
Study: 11991371

Group type: EXPERIMENTAL
Intervention: Wavelet transform of heart rate intervals for automatic AF detection
Number of subjects: 80
Study: 9951469

Group type: EXPERIMENTAL
Intervention: Surodex (dexamethasone 60 micrograms) inserted in the anterior chamber of 32 eyes, followed by placebo eyedrops four times a day for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops prescribed four times a day for 4 weeks (control group).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surodex (dexamethasone 60 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops
Number of subjects: 60
Study: 7479200

Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g plus tazobactam 500 mg by intravenous intermittent infusion every 8 hours
Number of subjects: 18
Study: 2320708

Group type: EXPERIMENTAL
Intervention: 0.25 mg q8h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.5 mg q8h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2 mg q12h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study: 7367815

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Anticholinergic drug therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bed rest in hospital
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Advice to cease smoking
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ulcer size
Number of subjects: 54
Study: 30419498

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU/wk)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28132574

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT) using Lokomat device
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional gait training (Control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups received 30 min of conventional exercise program (CEP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT)
Number of subjects: 38
Study: 25967465

Group type: EXPERIMENTAL
Intervention: Novel guide-wire technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 50
Study: 22581193

Group type: EXPERIMENTAL
Intervention: Traditional rotator training combined with heavy load eccentric training (TT + ET)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional rotator cuff training (TT)
Number of subjects: 61
Study: 21318559

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost at 0.5 µg/kg every 2 hours
Number of subjects: 15
Study: 19732457

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 0
Study: 17355742

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 15901125

Group type: EXPERIMENTAL
Intervention: 2500-Hz AC
Number of subjects: 23

Group type: COMPARATOR
Intervention: 3750-Hz AC
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5000-Hz AC
Number of subjects: 23
Study: 11956265

Group type: EXPERIMENTAL
Intervention: High-dose rIFN alpha-2b
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Low-dose rIFN alpha-2b
Number of subjects: 642

Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: ECS in lymph nodes
Number of subjects: 642
Study: 9838912

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional antiemetics
Number of subjects: 41
Study: 8559919

Group type: EXPERIMENTAL
Intervention: Imedeen (food supplement)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2235345

Group type: EXPERIMENTAL
Intervention: Z-30 (30 micrograms injections of Z-100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Z-20 (20 micrograms injections of Z-100)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IN (inosine)
Number of subjects: 0
Study: 427822

Group type: EXPERIMENTAL
Intervention: iv melphalan
Number of subjects: 425

Group type: COMPARATOR
Intervention: oral L‐PAM
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: oral L‐PAM after iv L‐PAM
Number of subjects: 425
Study: 31490342

Group type: EXPERIMENTAL
Intervention: Daily regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Time-driven regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Event-driven regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Participants reporting stimulant use
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Participants reporting other nonalcohol drug use
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Participants reporting no substance use
Number of subjects: 178
Study: 29244042

Group type: EXPERIMENTAL
Intervention: Nursing intervention (patient education and individualized nursing support during a 6-month rehabilitation period)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 36
Study: 26044145

Group type: EXPERIMENTAL
Intervention: Caraway oil poultices (CarO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hot olive oil poultice (OlivH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonheated olive oil poultice (OlivC)
Number of subjects: 48
Study: 23821401

Group type: COMPARATOR
Intervention: Flow-mediated dilatation (FMD) measurements
Number of subjects: 67
Study: 21685654

Group type: EXPERIMENTAL
Intervention: Emotionally charged verbal exchange first (followed by a more neutral verbal exchange)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotionally neutral verbal exchange first (followed by an emotionally charged verbal exchange)
Number of subjects: 0
Study: 19543092

Group type: EXPERIMENTAL
Intervention: Home walking intervention after outpatient cardiac rehabilitation for 12 weeks
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Home walking intervention
Number of subjects: 153
Study: 17181383

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 100-800 microg
Number of subjects: 0
Study: 15516774

Group type: EXPERIMENTAL
Intervention: TabAll tableting process analyzer
Number of subjects: 0
Study: 11027754

Group type: EXPERIMENTAL
Intervention: 1‐incision endoscopic technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2‐incision technique
Number of subjects: 20
Study: 8930858

Group type: EXPERIMENTAL
Intervention: DSS consultation
Number of subjects: 16
Study: 1841788

Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg/daily
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg/daily
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg/daily combined with indobufen 400 mg/daily
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/daily
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: low saturated fat and low cholesterol diet
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Control group (not treated with bezafibrate)
Number of subjects: 2356
Study: 6195483

Group type: EXPERIMENTAL
Intervention: Prizidilol 200 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prizidilol 400 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prizidilol 400 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30654780

Group type: EXPERIMENTAL
Intervention: LHW-delivered care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient facility-based care
Number of subjects: 0
Study: 28538088

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25239172

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 20 mL of saline water (placebo)
Number of subjects: 45
Study: 25355252

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Perconditioning (RIPerC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Postconditioning (RIPostC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 46
Study: 22206591

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy combined with health education for 6 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 125
Study: 20593353

Group type: EXPERIMENTAL
Intervention: Group J (Maquet Quardox)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group A (Affinity NT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group P (Polystan Safe Maxi)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group T (Terumo Capiox SX 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group C (COBE APEX‐TM)
Number of subjects: 40
Study: 18838662

Group type: EXPERIMENTAL
Intervention: Subjective cognitive failures (SCF)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Subjective memory failures (SMF)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Good objective cognitive performance
Number of subjects: 503

Group type: COMPARATOR
Intervention: Poor objective cognitive performance
Number of subjects: 503
Study: 16037145

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 microg x kg(‐1) x min(‐1) plus 10 microg demands
Number of subjects: 200

Group type: COMPARATOR
Intervention: Remifentanil 0.1 microg x kg(‐1) x min(‐1) plus 10 microg demands
Number of subjects: 200
Study: 11981083

Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg bolus and 0.25 mg/kg/h continuous infusion for up to 96 h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 56
Study: 10619543

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (8-week program including progressive muscle relaxation, guided imagery, self-instruction training, study and test-taking skills)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (untreated, N = 16)
Number of subjects: 27
Study: 7552768

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.05 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2191991

Group type: EXPERIMENTAL
Intervention: HEPA filter
Number of subjects: 32

Group type: COMPARATOR
Intervention: Blank filter (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HEPA filter (active)
Number of subjects: 32
Study: 175726

Group type: EXPERIMENTAL
Intervention: Oral adrenergic substances (e.g., ephedrine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors (e.g., theophylline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard dosage combination of oral adrenergic drugs and xanthines
Number of subjects: 0
Study: 31086347

Group type: EXPERIMENTAL
Intervention: Nivolumab without induction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nivolumab with cisplatin induction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nivolumab with doxorubicin induction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nivolumab with cyclophosphamide induction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nivolumab with irradiation (3 × 8 Gy) induction
Number of subjects: 67
Study: 27904156

Group type: EXPERIMENTAL
Intervention: Benidipine plus thiazide
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Benidipine plus β-blocker
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Benidipine plus ARB
Number of subjects: 3001
Study: 24942223

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 30
Study: 23296817

Group type: EXPERIMENTAL
Intervention: High energy diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low energy diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low energy diet + ovine leptin (oLeptin)
Number of subjects: 36
Study: 22077236

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441
Study: 19048338

Group type: EXPERIMENTAL
Intervention: Multimodality management regime (tape impregnated with agents providing an occlusive dressing)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tape and gel treatment (Group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Treated groups (various treatments across groups)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Historical outcomes for hypertrophic scarring (Group 4)
Number of subjects: 120
Study: 23298499

Group type: EXPERIMENTAL
Intervention: Variofill (2 ml injections, 2 injections in right knee)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Synvisc (2 ml injections, 2 injections in left knee)
Number of subjects: 20
Study: 15943852

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (group B)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Histamine(2)-receptor antagonist (famotidine)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Proton-pump inhibitors
Number of subjects: 320

Group type: COMPARATOR
Intervention: No eradication (group A)
Number of subjects: 320
Study: 12799209

Group type: EXPERIMENTAL
Intervention: Lenercept 0.125 mg/kg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 9872247

Group type: EXPERIMENTAL
Intervention: prtF1-containing strains
Number of subjects: 67

Group type: COMPARATOR
Intervention: Successful eradication
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Persisting strains
Number of subjects: 67
Study: 7699494

Group type: EXPERIMENTAL
Intervention: 1-minute increment intervals of midazolam (1 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 3-minute increment intervals of midazolam (1 mg)
Number of subjects: 26
Study: 2698569

Group type: EXPERIMENTAL
Intervention: 100 mg slow-release gallopamil (200 mg/day in two divided doses for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 269254

Group type: EXPERIMENTAL
Intervention: Brushes with 0.132 mm mean diameter nylon filaments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brushes with 0.280 mm diameter nylon filaments
Number of subjects: 0
Study: 12033699

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP), a seven-session intervention with parents and students together
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY), a five-session intervention focusing primarily on parents
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 33
Study: 29395121

Group type: EXPERIMENTAL
Intervention: VeriStrat Good classification
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: VeriStrat Poor classification
Number of subjects: 481
Study: 26963941

Group type: EXPERIMENTAL
Intervention: Eccentric overload training
Number of subjects: 20
Study: 25266425

Group type: EXPERIMENTAL
Intervention: 9-month afterschool PA program
Number of subjects: 221
Study: 22587425

Group type: EXPERIMENTAL
Intervention: Application of a circular plastic wound protector
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard abdominal wound edge protection with surgical dressings
Number of subjects: 516
Study: 20535051

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 477

Group type: COMPARATOR
Intervention: Simulated acupuncture treatment
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment after 1 treatment
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment after 5 treatments
Number of subjects: 477
Study: 18580523

Group type: EXPERIMENTAL
Intervention: Antegrade locked nailing
Number of subjects: 92

Group type: COMPARATOR
Intervention: Retrograde locked nailing
Number of subjects: 92
Study: 16306832

Group type: EXPERIMENTAL
Intervention: Positive selective nerve root injection (SNI) results
Number of subjects: 101

Group type: COMPARATOR
Intervention: Negative selective nerve root injection (SNI) results
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Positive magnetic resonance imaging (MRI) results
Number of subjects: 101

Group type: COMPARATOR
Intervention: Negative magnetic resonance imaging (MRI) results
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Surgery consistent with SNI findings
Number of subjects: 101

Group type: COMPARATOR
Intervention: Surgery inconsistent with SNI findings
Number of subjects: 101
Study: 12088919

Group type: EXPERIMENTAL
Intervention: 0.17 mg GH/day (starting dose), titrated by steps of 0.17 mg GH/day every 6-8 weeks, maintenance median GH dose of 0.33 mg/day in males and 0.83 mg/day in females
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy control subjects (17 subjects)
Number of subjects: 18